Update Botulinumtoxintherapie

Zusammenfassung

Drei Themen werden herausgegriffen, um die Optimierung der Botulinumtoxin(BTX)-Therapie zu diskutieren und zu zeigen, dass diesbezüglich noch viel Arbeit zu leisten ist: die funk-tionell-anatomische Organisation des KopfHals-Systems und die Injektion der tiefen Halsmuskulatur entsprechend dem neuen CAP/COL-Konzept, die Berücksichtigung verschiedener Armpositionsmuster bei der Injektion der Armspastik nach Schlaganfall und das frühzeitige Entdecken eines partiellen Therapieversagens zur Vermeidung hoher Antikörpertiter.

Summary

Even 30 years after first clinical applications of botulinum toxin aspects of optimization need to be discussed. For example, injection of deep neck muscles according to the new CAP/ COL-concept, injection of arm spasticity after stroke taking into account the difference in tone of five different arm position patterns as well as early detection of partial therapy failure to avoid complete treatment failure and high titers of neutralizing antibodies underline how much effort is still necessary to optimize BTX-therapy in clinical practice.

Schlüsselwörter

Tiefe Nackenmuskulatur - CAP/COL-Konzept - Armspastikmuster - Prävalenz neutralisierender Antikörper

Keywords

Deep neck muscles - CAP/COL-concept - spastic arm position patterns - prevalence of neutralizing antibodies

• Literatur

• 1 Chan J, Brin M, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord 1991; 6: 119-26.
• 2 Jankovic J. et al. Cervical dystonia: clinical findings and associated movement disorders. Neurology 1991; 41: 1088-91.
• 3 Van Zandijcke M. Cervical Dystonia (spasmodic torticollis). Some aspects of the natural history. Acta Neurol Belg 1995; 95: 210-5.
• 4 Tsui JK. et al. A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci 1985; 12: 314-6.
• 5 Simpson DM. et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70 (Suppl. 19) 1699-706.
• 6 Jost W. Klinische Anwendungen von Botulinumtoxin. Nervenarzt 2008; 79 (Suppl. 01) 9-14.
• 7 Hefter H. et al. A botulinum toxin A treatment algorithm for de novo management of torticollis and laterocollis. BMJopen 2011; 2: e000196.
• 8 Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with BTX A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 1999; 246: 265-74.
• 9 Giladi N. et al. Long-term remission of idiopathic cervical dystonia after treatment with BTX. Eur Neurol 2000; 44: 144-6.
• 10 Reichel G. Warum gibt es Therapieversager?. Nerve-narzt 2008; 79 (Suppl. 01) 33-5.
• 11 Swope D, Barbano R. Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystonia. Neurol Clin 2008; 26 (Suppl. 01) 43-53.
• 12 Jankovic J. Treatment of cervical dystonia. In: Brin MF, Comella C, Jankovic J. (eds.). Dystonia: Etiology, clinical features, and treatment. Philadelphia: Lippincott Williams & Wilkins; 2004
• 13 Benecke R, Moore P, Dressler D, Naumann M. Cervical and axial dystonia. In: Moore P, Naumann M. (eds.). Handbook of Botulinum Toxin Treatment. 2.nd ed. Malden: Blackwell Science; 2003
• 14 Dressler D. Botulinum Toxin Therapy. Stuttgart: Thieme; 2000
• 15 Koch LE, Korbmacher H, Kahl-Nieke B. A method for measuring head mobility in children and adults. Manuelle Medizin 2003; 41: 30-2.
• 16 Reichel G. Cervical dystonia: A new phenomenological classification for botulinum toxin therapy. Basal Ganglia 2011; 1: 5-12.
• 17 Hefter H. et al. CT-guided intramuscular botulinum toxin A injections into the deep anterior neck muscles in patients with pure antecaput or antecollis. Basal Ganglia 2012; 2 (Suppl. 02) 97-101.
• 18 Hefter H. et al. Impact of posterior neck muscle treatment on cervical dystonia: necessity to differentiate between abnormal positions of head and neck. Basal Ganglia 2012; 2 (Suppl. 02) 103-7.
• 19 Hefter H. et al. Classification of posture in post-stroke upper limb spasticity: a potential decision tool for botulinum toxin A treatment?. Int J Rehabil Res 2012; 35 (Suppl. 03) 227-33.
• 20 Bakheit AM. et al. The profile of patients and current practice of treatment of upper limb muscle spasticity with botulinum toxin type A: an international survey. Int J Rehabil Res 2010; 33 (Suppl. 03) 199-204.
• 21 Jost W. et al. Efficacy and safety of botulinum toxin A (Dysport) for the treatment of arm spasticity: Results of the German-Austrian open-label prospective survey. (submitted)
• 22 Hefter H. et al. Prospective analysis of neutralizing antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins – a single cohort 4-year follow-up study. BMJopen 2012; 2 (Suppl. 04) pii-e000646 doi: 10.1136/bmjopen-2011-000646.
• 23 Hefter H, Kahlen U, Moll M. Prevalence of neutralizing antibodies in a large cohort of long-term treated CD-patients. MDS congress Dublin 2012 Abstract 1032.